c-Myc modulation: a key role in melanoma drug response

Annalisa Fico, Daniela Alfano, Anna Valentino, Valeria Vasta, Ernesta Cavalcanti, Salvatore Travali, Eduardo J. Patriarca, Emilia Caputo

Research output: Contribution to journalArticle

Abstract

Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells. We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment. For the first time, we reported c-myc modulation is critical for melanoma drug response. It appeared drug-specific and post-transcriptionally driven through PP2A; in correlation, cell pre-treatment with okadaic acid (OA), a specific PP2A inhibitor, as well as PP2A silencing of melanoma cells, was able to increase melanoma cell drug-sensitivity and c-myc protein level. This is relevant for designing efficacious therapeutic strategies in melanoma.

Original languageEnglish
Pages (from-to)1375-1386
Number of pages12
JournalCancer Biology and Therapy
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 2 2015

Fingerprint

Melanoma
Pharmaceutical Preparations
Proto-Oncogene Proteins c-myc
temozolomide
Paclitaxel
Doxorubicin
Okadaic Acid
Drug Resistance
Hydrogen Peroxide
Phenotype

Keywords

  • B-RAF mutations
  • c-myc modulation
  • cancer therapy
  • chemotherapy
  • melanoma drug resistance, PP2A activity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Fico, A., Alfano, D., Valentino, A., Vasta, V., Cavalcanti, E., Travali, S., ... Caputo, E. (2015). c-Myc modulation: a key role in melanoma drug response. Cancer Biology and Therapy, 16(9), 1375-1386. https://doi.org/10.1080/15384047.2015.1030546

c-Myc modulation : a key role in melanoma drug response. / Fico, Annalisa; Alfano, Daniela; Valentino, Anna; Vasta, Valeria; Cavalcanti, Ernesta; Travali, Salvatore; Patriarca, Eduardo J.; Caputo, Emilia.

In: Cancer Biology and Therapy, Vol. 16, No. 9, 02.09.2015, p. 1375-1386.

Research output: Contribution to journalArticle

Fico, A, Alfano, D, Valentino, A, Vasta, V, Cavalcanti, E, Travali, S, Patriarca, EJ & Caputo, E 2015, 'c-Myc modulation: a key role in melanoma drug response', Cancer Biology and Therapy, vol. 16, no. 9, pp. 1375-1386. https://doi.org/10.1080/15384047.2015.1030546
Fico, Annalisa ; Alfano, Daniela ; Valentino, Anna ; Vasta, Valeria ; Cavalcanti, Ernesta ; Travali, Salvatore ; Patriarca, Eduardo J. ; Caputo, Emilia. / c-Myc modulation : a key role in melanoma drug response. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 9. pp. 1375-1386.
@article{74bc512b7162461994afb53097f5cceb,
title = "c-Myc modulation: a key role in melanoma drug response",
abstract = "Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells. We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment. For the first time, we reported c-myc modulation is critical for melanoma drug response. It appeared drug-specific and post-transcriptionally driven through PP2A; in correlation, cell pre-treatment with okadaic acid (OA), a specific PP2A inhibitor, as well as PP2A silencing of melanoma cells, was able to increase melanoma cell drug-sensitivity and c-myc protein level. This is relevant for designing efficacious therapeutic strategies in melanoma.",
keywords = "B-RAF mutations, c-myc modulation, cancer therapy, chemotherapy, melanoma drug resistance, PP2A activity",
author = "Annalisa Fico and Daniela Alfano and Anna Valentino and Valeria Vasta and Ernesta Cavalcanti and Salvatore Travali and Patriarca, {Eduardo J.} and Emilia Caputo",
year = "2015",
month = "9",
day = "2",
doi = "10.1080/15384047.2015.1030546",
language = "English",
volume = "16",
pages = "1375--1386",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - c-Myc modulation

T2 - a key role in melanoma drug response

AU - Fico, Annalisa

AU - Alfano, Daniela

AU - Valentino, Anna

AU - Vasta, Valeria

AU - Cavalcanti, Ernesta

AU - Travali, Salvatore

AU - Patriarca, Eduardo J.

AU - Caputo, Emilia

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells. We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment. For the first time, we reported c-myc modulation is critical for melanoma drug response. It appeared drug-specific and post-transcriptionally driven through PP2A; in correlation, cell pre-treatment with okadaic acid (OA), a specific PP2A inhibitor, as well as PP2A silencing of melanoma cells, was able to increase melanoma cell drug-sensitivity and c-myc protein level. This is relevant for designing efficacious therapeutic strategies in melanoma.

AB - Understanding molecular mechanisms involved in melanoma resistance to drugs is a big challenge. Experimental evidences suggested a correlation between mutational status in B-RAF and melanoma cell susceptibility to drugs, such as paclitaxel, doxorubicin and temozolomide, which generate an accumulation of hydrogen peroxide (H2O2) in the cells. We investigated the survival phenotype and the protein level of c-myc, a B-RAF target molecule, in melanoma cells, carrying a different mutational status in B-RAF, upon paclitaxel, doxorubicin and H2O2 treatment. For the first time, we reported c-myc modulation is critical for melanoma drug response. It appeared drug-specific and post-transcriptionally driven through PP2A; in correlation, cell pre-treatment with okadaic acid (OA), a specific PP2A inhibitor, as well as PP2A silencing of melanoma cells, was able to increase melanoma cell drug-sensitivity and c-myc protein level. This is relevant for designing efficacious therapeutic strategies in melanoma.

KW - B-RAF mutations

KW - c-myc modulation

KW - cancer therapy

KW - chemotherapy

KW - melanoma drug resistance, PP2A activity

UR - http://www.scopus.com/inward/record.url?scp=84941795525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941795525&partnerID=8YFLogxK

U2 - 10.1080/15384047.2015.1030546

DO - 10.1080/15384047.2015.1030546

M3 - Article

AN - SCOPUS:84941795525

VL - 16

SP - 1375

EP - 1386

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -